Single-vector rAAV9 gene replacement restores cardiac function in mouse model of LRPPRC mitochondrial disease
A preprint describes compact rAAV9 vectors that overcome LRPPRC's large coding sequence to rescue heart function and prevent early death in a tissue-specific knockout mouse.
A preprint posted to bioRxiv reports the development of a gene replacement strategy for LRPPRC-linked mitochondrial disease, a severe and currently incurable condition in which pathogenic variants disrupt mitochondrial gene expression, leading to neurological involvement alongside hepatopathy or cardiomyopathy.
A central technical obstacle to gene therapy for LRPPRC-related disease is that the LRPPRC coding sequence is too large to fit within the cargo capacity of adeno-associated virus (AAV) vectors when combined with conventional regulatory elements. The authors engineered compact single rAAV9 vectors — using abbreviated regulatory sequences — expressing either human or mouse LRPPRC, and administered them intravenously to mice with heart- and skeletal-muscle-specific Lrpprc knockout.
The approach restored cardiac LRPPRC expression, preserved heart function, and prevented the premature death seen in untreated knockouts. The strategy of compressing regulatory elements to accommodate large transgenes may have implications for gene therapy development in other mitochondrial and neuromuscular diseases where cargo size is similarly limiting.
This work is a preprint and has not yet completed peer review. The findings should be regarded as preliminary until independently evaluated.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary sourcePreprint bioRxiv (Cold Spring Harbor Laboratory) · 2026-11-13LRPPRC gene replacement therapy preserves cardiac function and prevents premature death in a mouse model of mitochondrial disease